See article by Jarreta et al. [4] ( pages 860 -865) in this by Jarreta et al. in this issue of Cardiovascular Research issue.
shows in both idiopathic dilated cardiomyopathy (IDC) and heart failure patients with a history of ischaemic Cardiac work is supported by a high rate of ATP coronary disease (IC) that the activity of complex III of the hydrolysis, matched by ATP production through mitoelectron transport chain is reduced, without changes in the chondrial oxidative phosphorylation (Fig. 1) . Low ATP activities of complexes I, II or IV, or in the mitochondrial content in cardiac tissue was observed in patients with marker enzyme citrate synthase [4] . Evidence for a causal chronic heart failure despite the absence of myocardial link between impaired mitochondrial metabolic function ischaemia [1] . Mitochondrial function in cardiac tissue and cardiac failure was found in several cases of inherited from the failing heart demonstrated that the capacity of the cardiomyopathies [5] , presenting as classic IDC. Surprismitochondria for oxygen consumption and oxidative phosingly little is known about the molecular aspects of phorylation are significantly reduced compared to the mitochondrial pathology in the failing heart. While point normal heart [2] . Furthermore, morphological examination mutations in key mitochondrial enzymes could signifiof the failing heart by electron microscopy revealed that cantly impair the ability of the mitochondria to generate the mitochondria are disrupted and damaged [3] . The paper ATP, Jarreta et al. [4] found only neutral polymorphisms in the mitochondrial cytochrome b gene, suggesting that the complex III defect is not a primary mitochondrial disease. A myriad of good questions is raised by the work of Jarreta et al. [4] . Are there functional consequences of the complex III defect? Is a 35% reduction in activity enough to result in a decrease in the rate of oxidative phosphorylation and a meaningful drop in the ATP content? Of interest, cardiomyopathy is not a presentation in patients with a congenital complex III defect [6] . The molecular cause of this decrease in complex III activity in heart failure is not known. Complex III contains 11 subunits, and the only one that is encoded on mitochondrial DNA, normal. The status of the other subunits needs to be determined before the molecular mechanism(s) can be fully understood. Additionally, the mitochondria in the heart *Corresponding author. Tel.: 11-216-368-5585; fax: 11-216-368-exist as two populations (interfibrillar and subsarcolem-
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E-mail address: wcs4@po.cwru.edu (W.C. Stanley) mal) which respond differently to inherited car-0008-6363 / 00 / $ -see front matter © 2000 Elsevier Science B. V. All rights reserved. PII: S0008-6363( 99 )00419-8 diomyopathy [7] , ischaemic injury [8] , and aging [9] . Is abnormalities, and determine the role they play in the there a selective decrease in complex III in only one progression of heart failure. Congestive heart failure is a population? Also, is there a greater production of free malignant disease and drugs that can stop the progression radicals due to the decreased complex III activity? of the disease are sorely needed. Therapies aimed at In addition to defects in the electron transport chain, the preserving mitochondrial function and optimizing substrate failing heart has important, clinically relevant mitochonmetabolism appear to be worthwhile pursuits in the effort drial abnormalities in the metabolism of carbon substrates to stop the progression of heart failure. for the generation of reducing equivalents (NADH and FADH ) (Fig. 1) . The oxidation of fatty acids normally 2 supplies approximately two thirds of the energy for References oxidative phosphorylation [10] . Heart failure patients may have impaired oxidation of glucose and lactate and en-
